Opsyon Project
print


Breadcrumb Navigation


Content

Team

Our team covers a broad spectrum of expertise and knowhow making it possible to design, engineer, develop and validate our antibody-fusion lead candidates OPS-121 for the treatment of AML and OPS-301 for the treatment of solid tumors. 

We are located at the Gene Center Munich and closely collaborating with the laboratories of Prof. Karl-Peter Hopfner granting access to equipment for protein engineering, purification and validation as well as scientific support. The close collaboration with Prof. Marion Subklewe, a leading and globally renown AML expert, involved in many clinical trials provides clinical experience, allows access to AML patient material and flow cytometry facilities. 

Dr. Nadja Fenn - Project Leader

Dr. Nadja Fenn

Project leader

+49 (0)89 2180 76962

nfenn@genzentrum.lmu.de

Dr. Lorenza Wyder Peters Business Officer

Dr. Lorenza Wyder Peters

Business Officer

+49 (0)89 2180 76962

wyder@genzentrum.lmu.de

Dr. Enrico Perini - Scientist Drug Development

Dr. Enrico Perini

Scientist Drug Development

+49 (0)89 2180 76844

perini@genzentrum.lmu.de

Dr. Björn Hiller - Scientist Immunology

Dr. Björn Hiller

Scientist Immunology

+49 (0)89 2180 76842

hiller@genzentrum.lmu.de